Case series will explore feasibility of robotic assistance and FFRct
Waltham, MA – October 23, 2017 – Corindus Vascular Robotics, Inc. [NYSE American: CVRS], a leading developer of precision vascular robotics, announced today that it will incorporate the HeartFlow® FFRct Analysis in a case series of robotic-assisted percutaneous coronary intervention (PCI) procedures with the CorPath® GRX System to evaluate the feasibility and utility of clinical decision support.
"We are pleased by this opportunity to incorporate the HeartFlow FFRct Analysis to advance our goal of improving patient outcomes in the cath lab through the synergistic use of this innovative non-invasive technology with our robotic platform," said Mark Toland, President and CEO of Corindus Vascular Robotics. "The integration of CorPath GRX with support tools that facilitate data-driven decision making, such as HeartFlow’s technology, helps standardize and optimize patient care. By enabling standardized treatment across patients, this care model could play an essential role in reducing overall procedural costs for hospitals."
The case series will be conducted by Steven Almany, M.D., at Beaumont Hospital, Troy, in Troy, Michigan, and Srini Potluri, M.D. at Baylor Scott & White The Heart Hospital – Plano in Plano, Texas. An initial visit has already been conducted at both sites. A demonstration model will also be available to view at TCT 2017 in the Corindus booth #3021 from October 30 to November 1.
"The objective of this case series is to demonstrate how the integration of multiple cutting-edge technologies can potentially improve patient outcomes," said Dr. Potluri. "Incorporating the HeartFlow FFRct Analysis into CorPath’s interventional cockpit combines an advanced pre-procedure planning tool with robotic precision to bring a new standard of care to patients."
CorPath GRX is the company’s second-generation robotic-assisted PCI technology, bringing robotic precision to interventional procedures to help optimize clinical outcomes and minimize the costs associated with complications of improper stent placement. With independent and simultaneous robotic control of guide catheters, guidewires, and balloon/stent catheters, physicians have the capability to perform a range of procedures, including complex cases, from the cockpit.
The HeartFlow FFRct Analysis is a non-invasive technology that provides insight into both the extent of coronary artery disease and the impact of the disease on blood flow to the heart. Data from a patient’s non-invasive coronary CT angiogram is securely uploaded from a hospital’s system to the cloud. Following this data transfer, HeartFlow leverages deep learning to create a personalized digital 3D model of the patient’s coronary arteries. It then uses powerful computer algorithms to solve millions of complex equations to simulate blood flow and assess the impact of blockages on coronary blood flow. The HeartFlow FFRct Analysis is provided via a secure web interface to the patient’s physician, who uses the information to design a definitive, personalized treatment plan.
"We expect the results of this case series to impact how we approach future patient care," added Dr. Almany. "Adopting new and advanced tools to support procedure decision making has the potential to improve patient outcomes now and shift our thinking toward a high-tech cardiovascular care model for the future."
Source: Corindus Vascular Robotics, Inc.
Physicians are members of the medical staff at one of Baylor Scott & White Health's subsidiary, community or affiliated medical centers and are neither employees nor agents of those medical centers, Baylor Scott & White The Heart Hospital – Plano or Baylor Scott & White Health.